Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
Cabaletta Bio (NASDAQ: CABA), a clinical-stage biotech company developing curative targeted cell therapies for autoimmune diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat on June 4, 2025, at 11:05 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through Cabaletta's website, with replays available for 30 days following the event.
Cabaletta Bio (NASDAQ: CABA), un'azienda biotecnologica in fase clinica che sviluppa terapie cellulari mirate e curative per le malattie autoimmuni, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. L'azienda parteciperà a una discussione informale il 4 giugno 2025, alle 11:05 ET a New York. Investitori e interessati potranno seguire la presentazione in diretta streaming sul sito web di Cabaletta, con la possibilità di rivedere la registrazione per 30 giorni dopo l'evento.
Cabaletta Bio (NASDAQ: CABA), una empresa biotecnológica en etapa clínica que desarrolla terapias celulares dirigidas y curativas para enfermedades autoinmunes, anunció su participación en la próxima Jefferies Global Healthcare Conference. La compañía participará en una charla informal el 4 de junio de 2025, a las 11:05 a.m. ET en Nueva York. Los inversores e interesados podrán acceder a una transmisión en vivo de la presentación a través del sitio web de Cabaletta, con repeticiones disponibles durante 30 días después del evento.
Cabaletta Bio (NASDAQ: CABA)는 자가면역 질환을 치료하는 표적 세포 치료제를 개발하는 임상 단계의 바이오텍 기업으로, 다가오는 Jefferies 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 2025년 6월 4일 오전 11시 05분(동부시간) 뉴욕에서 진행되는 파이어사이드 채팅에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Cabaletta 웹사이트를 통해 라이브 웹캐스트를 시청할 수 있으며, 행사 후 30일간 다시보기 서비스도 제공됩니다.
Cabaletta Bio (NASDAQ : CABA), une entreprise biotechnologique en phase clinique développant des thérapies cellulaires ciblées et curatives pour les maladies auto-immunes, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. La société participera à une discussion informelle le 4 juin 2025 à 11h05 (heure de l'Est) à New York. Les investisseurs et parties intéressées pourront accéder à une diffusion en direct de la présentation via le site web de Cabaletta, avec des rediffusions disponibles pendant 30 jours après l'événement.
Cabaletta Bio (NASDAQ: CABA), ein biotechnologisches Unternehmen in der klinischen Phase, das kurative, zielgerichtete Zelltherapien für Autoimmunerkrankungen entwickelt, gab seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt. Das Unternehmen wird am 4. Juni 2025 um 11:05 Uhr ET in New York an einem Fireside-Chat teilnehmen. Investoren und Interessierte können die Präsentation live über die Website von Cabaletta verfolgen, mit Wiedergaben, die bis zu 30 Tage nach der Veranstaltung verfügbar sind.
- None.
- None.
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, please visit www.cabalettabio.com and connect with us on LinkedIn.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
FAQ
When is Cabaletta Bio (CABA) presenting at the Jefferies Healthcare Conference 2025?
How can I watch Cabaletta Bio's (CABA) presentation at the Jefferies Conference?
What type of therapies is Cabaletta Bio (CABA) developing?
What is Cabaletta Bio's (CABA) current development stage?
